The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 2, 2012, Pages 253-257

  Lee, Illkyu O ^a   Kratz, Mario T ^a   Schirmer, Stephan H ^a   Baumhäkel, Magnus ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CARBACHOL; COLLAGEN; DABIGATRAN ETEXILATE; GLYCERYL TRINITRATE; HYDROETHIDINE; PHENYLEPHRINE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HEART RATE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; THROMBIN TIME; TREATMENT DURATION; VASCULAR RING; VASOCONSTRICTION; WILD TYPE;

ANIMALS; ANTITHROMBINS; APOLIPOPROTEINS E; BENZIMIDAZOLES; BETA-ALANINE; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN; ENDOTHELIUM, VASCULAR; ETHIDIUM; FLUORESCENT DYES; HEART RATE; MALE; MICE; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; THROMBIN;

EID: 84867614348     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.194837     Document Type: Article

References (34)

1. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H, and Blessing E (2006) Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 26:2787-2792.
2. Bizios R, Lai L, Fenton JW 2nd, and Malik AB (1986) Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol 128:485-490. (Pubitemid 16015533)
3. Borissoff JI, Loubele ST, Leenders P, Soehnlein O, Koenen RR, van Oerle R, Hamulyak K, Heeneman S, Daemen MJ, Weiler H, et al. (2010) Abstract 19384: Direct thrombin inhibition by dabigatran protects against severe atherosclerosis progression in prothrombotic mice. Circulation 122:A19384.
4. Borissoff JI, Spronk HM, Heeneman S, and ten Cate H (2009) Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res 82:392-403.
5. Chambers RC, Dabbagh K, McAnulty RJ, Gray AJ, Blanc-Brude OP, and Laurent GJ (1998) Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 333:121-127. (Pubitemid 28342501)
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, and Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators (2010) Newly identified events in the RE-LY trial. N Engl J Med 363:1875-1876.
8. Dabbagh K, Laurent GJ, McAnulty RJ, and Chambers RC (1998) Thrombin stimulates smooth muscle cell procollagen synthesis and mRNA levels via a PAR-1 mediated mechanism. Thromb Haemost 79:405-409. (Pubitemid 28065893)
9. Derkach DN, Ihara E, Hirano K, Nishimura J, Takahashi S, and Kanaide H (2000) Thrombin causes endothelium-dependent biphasic regulation of vascular tone in the porcine renal interlobar artery. Br J Pharmacol 131:1635-1642. (Pubitemid 32056429)
10. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, and Willerson JT (1989) Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 84:18-27. (Pubitemid 19170090)
11. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417-430.
12. Eto M, Barandiér C, Rathgeb L, Kozai T, Joch H, Yang Z, and Lüscher TF (2001) Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 89:583-590. (Pubitemid 32924212)
13. Furie B and Furie BC (1992) Molecular and cellular biology of blood coagulation. N Engl J Med 326:800-806.
14. Harker LA, Hanson SR, and Runge MS (1995) Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 75:12B-17B.
15. Harrison D, Griendling KK, Landmesser U, Hornig B, and Drexler H (2003) Role of oxidative stress in atherosclerosis. Am J Cardiol 91:7A-11A. (Pubitemid 36351457)
16. Hatton MW, Moar SL, and Richardson M (1989) Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 135:499-508. (Pubitemid 19246208)
17. Hirano K (2007) The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 27:27-36.
18. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, and Connolly SJ (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125:669-676.
19. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
20. Ivey ME and Little PJ (2008) Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. Thromb Res 123:288-297.
21. Laufs U, Wassmann S, Czech T, Münzel T, Eisenhauer M, Böhm M, and Nickenig G (2005) Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol 25:809-814. (Pubitemid 40463874)
22. Love JE, Ferrell C, and Chandler WL (2007) Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 98:234-242.
23. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, et al. (2004) Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110:3708-3714. (Pubitemid 39665261)
24. Nagy N, Grandoch M, and Fischer J (2011) Abstract 15194: Dabigatran causes remodelling of plaque extracellular-matrix in diabetogenic low density lipoprotein-receptor knockout mice. Circulation 124:A15194.
25. Preusch M, Wijelath E, Murray J, Cabbage S, Ieronimakis N, Callegari A, Bea F, Blessing E, Reyes M, van Ryn J, et al. (2010) Dabigatran etexilate, a new oral thrombin inhibitor, retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice, at the Arteriosclerosis, Thrombosis, and Vascular Biology 2010 Scientific Sessions; 2010 April 8-10; San Francisco, CA. American Heart Association, Dallas, TX.
26. Schirmer SH, Baumhäkel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, and Böhm M (2010) Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol 56:2067-2076.
27. Stangier J and Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23:138-143.
28. Uchino K and Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397-402.
29. van der Poll T, de Boer JD, and Levi M (2011) The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis 24:273-278.
30. Wassmann S, Czech T, van Eickels M, Fleming I, Böhm M, and Nickenig G (2004a) Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110:3062-3067. (Pubitemid 39491999)
31. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M, and Nickenig G (2004b) Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94:534-541. (Pubitemid 38326289)
32. Watts VL and Motley ED (2009) Role of protease-activated receptor-1 in endothelial nitric oxide synthase-Thr495 phosphorylation. Exp Biol Med (Maywood) 234:132-139.
33. Wienen W, Stassen JM, Priepke H, Ries UJ, and Hauel N (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155-162. (Pubitemid 47078782)
34. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, Humphrey JD, and Kuo L (2004) Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44:935-943. (Pubitemid 39577425)